Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs AT&T Inc. — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $111.12 (market cap $12.58B), while AT&T Inc. trades at $22.73 (market cap $170.42B). The key difference: AT&T Inc. is far larger — about 13.5× Halozyme Therapeutics Inc. Common Stock's market cap, and AT&T Inc. pays a 4.46% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and AT&T Inc. for 118 Days on average.
| HALO | T | |
|---|---|---|
Market Cap | $12.58B | $170.42B |
Volume | 2,179,278 | 50,780,036 |
Sector | Health | Media |
52-Week High | $115.22 | $29.10 |
52-Week Low | $61.63 | $20.49 |
Typical Hold Time | 0 Days | 118 Days |
Enterprise Value | $14.49B | $315.74B |
Dividend Yield | — | 4.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
AT&T (T) trades at $24.48, up 0.2% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 8.2, 16.9% net margin, and consistent dividend payments. Revenue grew to $125.7B in 2025, while debt reduction and fiber expansion with Corning highlight strategic initiatives. Analyst consensus is mixed with 44% buy ratings and a $27.61 price target.
The outlook balances value appeal against competitive pressures. The low valuation and 4% yield attract income investors, but legacy revenue declines and high debt pose risks. Fiber investments and wireless growth offer upside, yet execution and market saturation remain challenges. The stock presents a dividend-income opportunity with moderate growth potential in a competitive telecom landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
